Trends in Nanotechnology for in vivo Cancer Diagnosis: Products and Patents.

abstract：:Mediation of antinociception via opioid receptors located in the periphery is a viable strategy to produce analgesia without the occurrence of side effects associated with stimulation of opioid receptors located in the central nervous system. Peripheral opioid receptors are particularly important in inflammatory pain ...

journal_title：Current pharmaceutical design

authors： DeHaven-Hudkins DL,Dolle RE

更新日期：2004-01-01 00:00:00

abstract：:Repurposing already approved drugs as new anticancer agents is a promising strategy considering the advantages such as low costs, low risks and less time-consumption. Disulfiram (DSF), as the first drug for antialcoholism, was approved by the U.S. Food and Drug Administration (FDA) over 60 years ago. Increasing eviden...

journal_title：Current pharmaceutical design

authors： Yang Q,Yao Y,Li K,Jiao L,Zhu J,Ni C,Li M,Dou QP,Yang H

更新日期：2019-01-01 00:00:00

abstract：:Fusion proteins have been well-studied and widely applied in biopharmaceutics. Albumin fusion proteins are simple to construct, easy to purify, and stable to formulate. One main application of fusion protein is to extend the plasma half-life of therapeutic proteins and peptides. Albiglutide for diabetes treatment is t...

journal_title：Current pharmaceutical design

authors： Rogers B,Dong D,Li Z,Li Z

更新日期：2015-01-01 00:00:00

abstract：:Heat shock proteins (HSPs) are involved in a number of cellular processes, including cell cycle, growth, and survival, apoptosis, stress responses, angiogenesis, and oncogenesis. Among the characterized HSPs, the molecular chaperone HSP90 has emerged as an exciting molecular target for cancer therapy since its discove...

journal_title：Current pharmaceutical design

authors： Kondoh Y,Osada H

更新日期：2013-01-01 00:00:00

abstract：:Chemokines and their receptors play critical roles in leukocyte trafficking during inflammatory processes. Although the role of chemokine receptors (CKRs) in cancer biology is a relatively new field of study, a growing body of data suggest that a number of CKRs, including CXCR4, CCR4, CCR7, and CCR10, may play diverse...

journal_title：Current pharmaceutical design

authors： Wu X,Lee VC,Chevalier E,Hwang ST

更新日期：2009-01-01 00:00:00

abstract：:Agitation is commonly seen in acute schizophrenic patients and core symptoms include a wide range of symptom. It requires rapid and effective treatment approaches in order to protect patient and caregiver from potential injury. Clinician's decision of pharmacological treatment should be individualized to the needs and...

journal_title：Current pharmaceutical design

authors： San L,Arranz B,Escobar R

更新日期：2005-01-01 00:00:00

abstract：BACKGROUND AND OBJECTIVES:The 3' repair exonuclease 1 (TREX1) gene is the major DNA-specific 3'-5 'exonuclease of mammalian cells which reduces single- and double-stranded DNA (ssDNA and dsDNA) to prevent undue immune activation mediated by the nucleic acid. TREX1 is also a crucial suppressor of selfrecognition that pr...

journal_title：Current pharmaceutical design

authors： Tao SS,Wu GC,Zhang Q,Zhang TP,Leng RX,Pan HF,Ye DQ

更新日期：2019-01-01 00:00:00

abstract：BACKGROUND:Cancer and its treatment therapies, such as chemotherapy and radiotherapy, have negative effects on taste and smell functions. It is easy to explain smell and taste dysfunctions when a cancer involves the peripheric end organs or neurologic pathways of smell and taste. However, it is difficult to understand ...

journal_title：Current pharmaceutical design

authors： Altundag A,Cayonu M

更新日期：2016-01-01 00:00:00

abstract：:DNA methyltransferase (DNMT) and histone deacetylase are key enzymes mediating the epigenetic regulation of gene expression. DNA hypermethylation and/or histone deacetylation in promoter regions is often associated with downregulation or silencing of transcription. Epigenetic silencing of tumor suppressor genes plays ...

journal_title：Current pharmaceutical design

authors： Xu S,Ren J,Chen HB,Wang Y,Liu Q,Zhang R,Jiang SW,Li J

更新日期：2014-01-01 00:00:00

abstract：:Nucleosides constitute an extensive group of natural and chemically modified compounds that display a wide range of structures and activities. Different biocatalysts have been developed for their preparation, but the choice of commercially available enzymes is limited. Therefore, the search of new biocatalysts is part...

journal_title：Current pharmaceutical design

authors： Lewkowicz ES,Iribarren AM

更新日期：2017-10-11 00:00:00

abstract：:Although escape from tumor dormancy has long been recognized as an important problem in the treatment of cancer, the molecular and cellular regulators underlying this transition remain poorly understood. The inability of the cancer cells to induce a complete and successful process of angiogenesis can result in tumor d...

journal_title：Current pharmaceutical design

authors： Shaked Y,McAllister S,Fainaru O,Almog N

更新日期：2014-01-01 00:00:00

abstract：:Hyperglycemia is a common feature of the critically ill in general and of patients with sepsis in particular. Even a moderate degree of hyperglycemia appears detrimental for the outcome of critically ill patients, since maintenance of normoglycemia (blood glucose levels

journal_title：Current pharmaceutical design

authors： Van Cromphaut SJ,Vanhorebeek I,Van den Berghe G

更新日期：2008-01-01 00:00:00

abstract：:Since their proposal in 1976, sigma (σ) receptors have been increasingly implicated in the pathophysiology of virtually all major central nervous system (CNS) disorders, including anxiety, depression, schizophrenia, and drug addiction. Due to their involvement in motor function and higher cognitive function,σ recepto...

journal_title：Current pharmaceutical design

authors： Banister SD,Kassiou M

更新日期：2012-01-01 00:00:00

abstract：BACKGROUND:Fragile X syndrome (FXS) is the most common form of monogenic hereditary cognitive impairment, including intellectual disability, autism, hyperactivity, and epilepsy. METHODS:This article reviews the literature pertaining to the role of synaptic dysfunction in FXS. RESULTS:In FXS, synaptic dysfunction alte...

journal_title：Current pharmaceutical design

authors： Telias M

更新日期：2019-01-01 00:00:00

abstract：:Evasion of apoptosis, the cell's intrinsic death program, is a hallmark of human cancers including neuroblastoma. Also, failure to undergo apoptosis may cause treatment resistance, since the cytotoxic activity of anticancer therapies commonly used in the clinic, e.g. chemotherapy, gamma-irradiation or immunotherapy, i...

journal_title：Current pharmaceutical design

authors： Fulda S

更新日期：2009-01-01 00:00:00

abstract：BACKGROUND:Intracerebral hemorrhage is one of the most common injuries in vehicle accidents. The aim of this paper is to survey the injury mechanism of intracerebral hemorrhage in vehicle accidents, including contusion, subarachnoid hemorrhage (SAH), subdural hematoma (SDH) and diffuse axonal injury (DAI). METHODS:A c...

journal_title：Current pharmaceutical design

authors： Li F,Li H,Xiao Z,Lu R,Zhang Z,Zhu H,Ren L

更新日期：2017-01-01 00:00:00

abstract：:Inhaled glucocorticoids, also know as corticosteroids (ICS), revolutionized the treatment of asthma by suppressing airways inflammation and ICS therapy now forms the basis of treatment of asthma of all severities. More recently and usually in combination with a long-acting β-agonist (LABA), ICS use has been establishe...

journal_title：Current pharmaceutical design

authors： Adcock IM,Marwick J,Casolari P,Contoli M,Chung KF,Kirkham P,Papi A,Caramori G

更新日期：2010-01-01 00:00:00

abstract：:Research on Substance P (SP) has, until recently, focused on its role in pain and inflammation. However, a report that NK(1) receptor antagonists have utility in the treatment of depression has stimulated research into the function of SP and the NK(1)receptor in anxiety and depression. The distribution of SP and the N...

journal_title：Current pharmaceutical design

authors： McLean S

更新日期：2005-01-01 00:00:00

abstract：:Monocytes are leading component of the mononuclear phagocytic system that play a key role in phagocytosis and removal of several kinds of microbes from the body. Monocytes are bone marrow precursor cells that stay in the blood for a few days and migrate towards tissues where they differentiate into macrophages. Monocy...

journal_title：Current pharmaceutical design

authors： Sabir F,Farooq RK,Asim Ur Rehman,Ahmed N

更新日期：2018-01-01 00:00:00

abstract：:Alzheimer's disease (AD) is the most common form of dementia in the elderly. Research focused on identifying compounds that restore cognition and memory in AD patients is a very active investigational pursuit, but unfortunately, it has been only successful in terms of developing symptomatic treatments. Aβ deposition a...

journal_title：Current pharmaceutical design

authors： Solas M,Puerta E,Ramirez MJ

更新日期：2015-01-01 00:00:00

abstract：:Over the last years a number of reports have described elevated numbers of regulatory T (Treg) cells inside of tumors, in close proximity of the tumor, draining lymph nodes and also in peripheral blood of patients with solid tumors and hematologic malignancies. There is increasing evidence that Treg cells can migrate ...

journal_title：Current pharmaceutical design

authors： Beyer M,Schultze JL

更新日期：2009-01-01 00:00:00

abstract：:Aquaporins (AQPs) are expressed in physiologically essential tissues and organs in which edema and fluid imbalances are of major concern. Potential roles in brain water homeostasis and edema, angiogenesis, cell migration, development, neuropathological diseases, and cancer suggest that this family of membrane proteins...

journal_title：Current pharmaceutical design

authors： Yool AJ

更新日期：2007-01-01 00:00:00

abstract：:The beneficial effect of antihypertensive treatment on the risk of major vascular events is well established. Several trials comparing older and newer drugs in the treatment of primary hypertension suggested that it is the blood pressure achieved, rather than choice of the drug that determines most of the primary outc...

journal_title：Current pharmaceutical design

authors： Karagiannis A,Mikhailidis DP,Kakafika AI,Tziomalos K,Athyros VG

更新日期：2007-01-01 00:00:00

abstract：:About 50 peptides, and a similar number of peptide receptors, are known to be present in the gut and this amount is likely to rise significantly over the next few years. While there has been a massive research effort to define their functions and their anatomical distribution in the central nervous system (CNS), the u...

journal_title：Current pharmaceutical design

authors： Motilva V,Talero E,Calvo JR,Villegas I,Alarcón-de-la-Lastra C,Sánchez-Fidalgo S

更新日期：2008-01-01 00:00:00

abstract：:A wide range of peptides and polypeptides can be appended to either the N- or C-terminus of G protein-coupled receptors without disrupting substantially ligand binding and signal transduction. Following fusion of fluorescent proteins, reporter gene constructs or G protein alpha subunits to the C-terminal tail of a rec...

journal_title：Current pharmaceutical design

authors： Milligan G,Feng GJ,Ward RJ,Sartania N,Ramsay D,McLean AJ,Carrillo JJ

更新日期：2004-01-01 00:00:00

abstract：:Osteoblasts pass through a sequence of events controlled by hormones and transcriptional factors ensuring proper development of phenotype and functional properties until the osteoblast enter the osteocyte phenotype and/or undergo apoptosis. During its life cycle, the osteoblasts proliferate, deposit matrix proteins an...

journal_title：Current pharmaceutical design

authors： Gordeladze JO,Reseland JE,Drevon CA

更新日期：2001-03-01 00:00:00

abstract：:Neuromuscular blocking agents are the leading drugs responsible for immediate hypersensitivity reactions during anaesthesia. Most hypersensitivity reactions represent IgE-mediated allergic reactions. Their incidence is estimated to be between 1 in 3,000 to 1 in 110,000 general anaesthetics. However striking variations...

journal_title：Current pharmaceutical design

authors： Mertes PM,Aimone-Gastin I,Guéant-Rodriguez RM,Mouton-Faivre C,Audibert G,O'Brien J,Frendt D,Brezeanu M,Bouaziz H,Guéant JL

更新日期：2008-01-01 00:00:00

abstract：:In recent years, combination of different types of therapies using nanoparticles has emerged as an advanced strategy for cancer treatment. Most of all, combination of chemotherapeutic drug and siRNA in nanoformulation has shown a great potential, because siRNA-mediated specific gene silencing can compensate for the in...

journal_title：Current pharmaceutical design

authors： Yhee JY,Son S,Lee H,Kim K

更新日期：2015-01-01 00:00:00

abstract：BACKGROUNDS:Targeted therapy is the foundation of personalized medicine in cancer, which is often understood as the right patient using the right drug. Thinking from the viewpoint of determinants during personalized drug treatment, the genetics, epigenetics and metagenomics would provide individual-specific biological ...

journal_title：Current pharmaceutical design

authors： Wang L,Yu X,Zhang C,Zeng T

更新日期：2018-01-01 00:00:00

abstract：:Prostacyclin (PGI(2)) is one of the major vascular protectors against thrombosis and vasoconstriction, caused by thromboxane A(2). Understanding the molecular mechanisms of PGI(2) biosynthesis and signaling is crucial to the development of therapeutic approaches to regulate PGI(2) functions. This review provides infor...

journal_title：Current pharmaceutical design

authors： Ruan KH,Dogné JM

更新日期：2006-01-01 00:00:00